Your browser doesn't support javascript.
loading
Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails.
Brandum, Emma Probst; Jørgensen, Astrid Sissel; Calvo, Marina Barrio; Spiess, Katja; Peterson, Francis C; Yang, Zhang; Volkman, Brian F; Veldkamp, Christopher T; Rosenkilde, Mette Marie; Goth, Christoffer Knak; Hjortø, Gertrud Malene.
Afiliação
  • Brandum EP; Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Jørgensen AS; Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Calvo MB; Evaxion Biotech A/S, 2970 Horsholm, Denmark.
  • Spiess K; Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Peterson FC; Virus and Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.
  • Yang Z; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Volkman BF; Copenhagen Center for Glycomics, University of Copenhagen, Noerregade 10, 1165 Copenhagen, Denmark.
  • Veldkamp CT; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Rosenkilde MM; Department of Chemistry, University of Wisconsin-Whitewater, Whitewater, WI 53190, USA.
  • Goth CK; Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Hjortø GM; Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Int J Mol Sci ; 23(3)2022 Jan 26.
Article em En | MEDLINE | ID: mdl-35163323
ABSTRACT
The chemokine receptor CCR7 and its ligands CCL19 and CCL21 regulate the lymph node homing of dendritic cells and naïve T-cells and the following induction of a motile DC-T cell priming state. Although CCL19 and CCL21 bind CCR7 with similar affinities, CCL21 is a weak agonist compared to CCL19. Using a chimeric chemokine, CCL19CCL21N-term|C-term, harboring the N-terminus and the C-terminus of CCL21 attached to the core domain of CCL19, we show that these parts of CCL21 act in a synergistic manner to lower ligand potency and determine the way CCL21 engages with CCR7. We have published that a naturally occurring basic C-terminal fragment of CCL21 (C21TP) boosts the signaling of both CCL19 and CCL21. Boosting occurs as a direct consequence of C21TP binding to the CCR7 N-terminus, which seems to free chemokines with basic C-termini from an unfavorable interaction with negatively charged posttranslational modifications in CCR7. Here, we confirm this using a CCL19-variant lacking the basic C-terminus. This variant displays a 22-fold higher potency at CCR7 compared to WT CCL19 and is highly unaffected by the presence of C21TP. WT CCL19 has a short basic C-terminus, CCL21 a longer one. Here, we propose a way to differentially boost CCL19 and CCL21 activity as short and long versions of C21TP boost CCL19 activity, whereas only a long C21TP version can boost chemokines with a full-length CCL21 C-terminus.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Quimiocina CCL19 / Quimiocina CCL21 / Receptores CCR7 Idioma: En Revista: Int J Mol Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Quimiocina CCL19 / Quimiocina CCL21 / Receptores CCR7 Idioma: En Revista: Int J Mol Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Dinamarca